FAIRFAX, Va. — Vibrent Health, a software-as-a-service data company focused on precision medicine research, said it is collaborating with Fred Hutch Cancer Center on a large-scale hybrid and remote decentralized clinical research study funded through a $17 million contract awarded by the Biomedical Advanced Research and Development Authority.
The study is being conducted under BARDA’s Rapid Response Partnership Vehicle Consortium and is focused on identifying correlates of protection, measurable immune markers that predict protective immunity against infectious diseases. The research uses decentralized clinical trial methods to collect and analyze real-world data from participants in their everyday environments.
“This research represents a pivotal step in understanding how the immune system responds to vaccines through the use of real-world data collected remotely,” said Praduman “PJ” Jain, CEO of Vibrent Health. “By identifying correlates of protection in a large population, we can drive innovation to improve public health preparedness for future infectious disease outbreaks.”
Traditional clinical trials often require participants to travel to centralized research sites, which can limit enrollment and diversity. Vibrent said its approach brings research directly to participants through digital engagement, remote biospecimen collection, and integrated real-world data capture, expanding access while accelerating scientific discovery.
“This study expands access, enhances flexibility of collecting high-quality data, and accelerates the development of next-generation therapeutics and prevention agents,” said Peter Gilbert, Principal Investigator of the study in the Vaccine and Infectious Disease Division at Fred Hutch. “By identifying and validating correlates of protection, this research not only informs the development of more targeted and effective treatments for infectious diseases but also establishes a framework that can be applied to a wide range of clinical trials, improving outcomes and speeding up the path to approval.”
Vibrent said the decentralized and hybrid trial model reduces the burden on participants and improves scalability and efficiency. The company’s role in the BARDA-funded study highlights how remote research approaches are shaping the future of infectious disease studies by enabling richer data collection and faster public health insights.
“Advancing clinical research requires a broad approach that allows for remotely collected real-world data while streamlining clinical operations to enhance efficiency and accelerate research outcomes,” said Jessica Andriesen, Director of Operations for the Statistical and Data Coordinating Center in the Vaccine and Infectious Disease Division at Fred Hutch. “In this study, we’re using new technology to integrate and analyze data in ways that are operationally efficient and lead to high-quality results.”
Vibrent’s research data management platform centralizes complex datasets to improve transparency for clinical staff and researchers. The platform integrates electronic patient-reported outcomes, electronic case report forms, biospecimen data, and operational metrics, supporting the generation of high-quality, reproducible data. The company also developed real-time dashboards that provide insights into trial performance, including participant enrollment and adverse event monitoring.
Vibrent said the same scalable model used in the BARDA-funded study can be applied to commercial studies across therapeutic areas including oncology, precision medicine, metabolic disorders, and neuroscience, positioning the company as a technology partner for decentralized and hybrid clinical trials.
